Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

Share Price is delayed by 15 minutes
Get Live Data
8.40    0.05 (0.60%)
Bid:
8.30
Ask:
8.50
Spread: 0.20 (2.41%)
Market Cap: £57.83m
HVO Live PriceLast checked at - London Stock Exchange

Intraday hVIVO Share Chart

Form 8 (OPD)

11 Dec 2019 07:00

RNS Number : 4280W
hVIVO plc
11 December 2019
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

hVIVO plc ("hVIVO")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

n/a

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

hVIVO plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

06/12/2019

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES - Open Orphan Plc

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

Nil

Nil

(2) Cash-settled derivatives:

 

Nil

Nil

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Nil

Nil

 

TOTAL:

Nil

Nil

Nil

Nil

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

Nil

Details, including nature of the rights concerned and relevant percentages:

Nil

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interests of hVIVO Directors in hVIVO shares:

Name

No. of shares

%

Dr Trevor Phillips

44,776

0.05

James Winschel

154,548

0.19

Dr Mark Warne

5,677

0.01

 

 Interests of hVIVO Directors in options over hVIVO shares:

Name

No. of options

Grant date

% vested

Expiry date

Exercise price (p)

Dr Trevor Phillips

850,000

20/12/17

nil

19/12/27

5p

Dr Trevor Nicholls

26,540

02/04/14

100

18/12/22

101.63p

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

11/12/2019

Contact name:

Anesh Patel (Interim Finance Director & Company Secretary)

Telephone number:

+44(0)207 148 1018

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEUROBRKOAUAAA
Date   Source Headline
1st Jun 202612:00 pmRNS-RConsultancy contract with Decoy Therapeutics
29th May 20267:00 amRNSGrant of awards under Long Term Incentive Plan
20th May 20267:00 amRNSCapital Markets Day
13th May 20261:40 pmRNSResult of AGM
12th May 20269:45 amRNSHolding(s) in Company
7th May 20267:00 amRNS£6m Influenza HCT contract signed
24th Apr 20266:14 pmRNSDirector/PDMR Shareholding
22nd Apr 20267:00 amRNSHCT contract signed with ILiAD Biotechnologies
17th Apr 20267:00 amRNSAnnual Report & Notice of AGM
15th Apr 20267:00 amRNSFinal Results 2025
14th Apr 20267:01 amRNS-RhVIVO launches unified brand identity
14th Apr 20267:00 amRNSInfluenza HCT contract signed with Traws Pharma
7th Apr 20267:00 amRNSNotice of Results
26th Mar 20265:19 pmRNSHolding(s) in Company
27th Feb 20263:31 pmRNSHolding(s) in Company
23rd Feb 20267:00 amRNSIssue of Equity and Total Voting Rights
16th Feb 20263:05 pmRNSHolding(s) in Company
11th Feb 20263:11 pmRNSHolding(s) in Company
29th Jan 20267:00 amRNSTrading Update
27th Jan 20267:00 amRNSNotice of Trading Update
18th Dec 20257:00 amRNSAppointment of Non-Executive Director
15th Dec 20252:47 pmRNSCEO & CFO Share Purchase
27th Nov 20257:00 amRNS-RMSD to acquire Cidara
20th Nov 20257:00 amRNS>£5 million CRS contracts signed
11th Nov 20257:00 amRNS-RPositive data from novel human challenge models
6th Nov 20255:05 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNS-RPresentation at Jefferies Healthcare Conference
27th Oct 20253:01 pmRNSHolding(s) in Company
23rd Sep 20257:00 amRNSInterim results
4th Sep 20257:00 amRNSNotice of Results
1st Sep 20257:00 amRNSAppointment of Non-Executive Chair
29th Jul 20257:00 amRNSProposed appointment of Chair
22nd Jul 20257:00 amRNSH1 Trading update
18th Jul 20257:00 amRNSDirectorate Change
9th Jul 20257:00 amRNSNotice of Trading Update
1st Jul 20254:04 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNS-RPositive results from client Phase 2b field study
5th Jun 20251:00 pmRNSResult of AGM
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSTrading update
29th May 20257:00 amRNSAppointment of Independent Non-Executive Director
12th May 20257:00 amRNSAnnual Report, Notice of AGM & Directorate Change
10th Apr 20257:05 amRNSExercise of Options
10th Apr 20257:00 amRNSFinal results
26th Mar 20251:51 pmRNSAIM Rule 17 and Schedule 2(g) Update
21st Mar 20257:00 amRNSNotice of Results
7th Mar 20257:00 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAcquisition of Cryostore for up to £3.2m
17th Feb 20257:00 amRNS£2m hMPV characterisation study contract
5th Feb 20257:00 amRNS-RShionogi reports positive RSV trial results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.